Hostname: page-component-6bf8c574d5-h6jzd Total loading time: 0.001 Render date: 2025-02-17T19:04:06.010Z Has data issue: false hasContentIssue false
  • English
  • Français

Response to concurrent cetuximab: radiotherapy following failure of platinum-based induction chemotherapy in squamous cell carcinoma of the larynx

Published online by Cambridge University Press:  22 April 2013

L. Pettit  and
P. Ramachandra
L. Pettit*
Affiliation:
Deansley Centre, Royal Wolverhampton Hospital, Wolverhampton, UK
P. Ramachandra
Affiliation:
Deansley Centre, Royal Wolverhampton Hospital, Wolverhampton, UK
*
Correspondence to: Dr Laura Pettit, Hall-Edwards Research Radiotherapy Group, Queen Elizabeth Hospital, Birmingham, UK. Tel: +44 (0) 7779089066. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Concurrent chemoradiation is the standard of care in the non-surgical management of locally advanced squamous cell carcinoma (SCC) of the larynx. Cetuximab can be used as an alternative to platinum for concomitant radiotherapy and the addition of cetuximab to cisplatin has been reported to improve response rates compared with cisplatin alone. We report two cases of patients who progressed through platinum-based induction chemotherapy and subsequently achieved a complete response with concurrent cetuximab radiotherapy.

Keywords

cetuximabchemoradiationsquamous cell carcinoma of the head and neck
Type
Case Study
Information
Journal of Radiotherapy in Practice , Volume 13 , Issue 1 , March 2014 , pp. 93 - 97
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685–1690.Google Scholar
2.Hanna, E, Sherman, A, Cash, Det al. Quality of life for patients following total laryngectomy vs. chemoradiation for laryngeal preservation. Arch Otolaryngol Head Neck Surg 2004; 130: 875–879.Google Scholar
3.Forastiere, A A, Goepfert, H, Maor, Met al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091–2098.CrossRefGoogle ScholarPubMed
4.Pointreau, Y, Garaud, P, Chapet, Set al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101 (7): 498–506.Google Scholar
5.Zhang, N, Erjala, K, Kulmala, Jet al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol 2009; 92 (3): 388–392.CrossRefGoogle ScholarPubMed
6.Bonner, J A, Harari, P M, Giralt, Jet al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–578.Google Scholar
7.Burtness, B, Goldwasser, M A, Flood, Wet al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2005; 23: 8646–8654; Erratum, J Clin Oncol 2006; 24: 724.CrossRefGoogle ScholarPubMed
8.Vermorken, J B, Trigo, J, Hitt, Ret al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171–2177.CrossRefGoogle ScholarPubMed
9.Baselga, J, Trigo, J M, Bourhis, Jet al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568–5577.Google Scholar
10.Herbst, R S, Arquette, M, Shin, D Met al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578–5587.CrossRefGoogle ScholarPubMed
11.Vermorken, J B, Mesia, R, Rivera, Fet al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116–1127.CrossRefGoogle ScholarPubMed
12.Bonner, J A, Harari, P M, Giralt, Jet al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11 (1): 21–28.CrossRefGoogle ScholarPubMed
13.Pignon, J P, le Maître, A, Maillard, Eet al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.Google Scholar
14.Ang, K K, Zhang, Q E, Rosenthal, D Iet al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III–IV head and neck squamous cell carcinomas. J Clin Oncol 2011; 29 (suppl., abstract 5500)Google Scholar
15.Lefebvre, J, Pointreau, Y, Rolland, Fet al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study. J Clin Oncol 2011; 29 (suppl., abstract 5501)CrossRefGoogle Scholar
16.Rampino, M, Bacigalupo, A, Russi, Eet al. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Res 2012; 32 (1): 195–200.Google ScholarPubMed